



**STEM CELL SOCIETY**  
SINGAPORE

## **STEM CELL SOCIETY SEMINAR ANNOUNCEMENT**

**22 March 2013, Friday, Aspiration** Theatre, Matrix Building **Level 2M**  
30 Biopolis Street, Singapore 138671

### **PROGRAMME**

**4.00 - 5.00pm**

**Dr. Natalie MOUNT**  
Chief Clinical Officer, Cell Therapy Catapult, UK

**"Accelerating Commercialisation of Cell Based Therapies"**

**5.00pm onwards**

**Networking** (brought to you by Stem Cell Society and Cell Therapy Catapult)

**Hosted by**

**Steve OH**  
Treasurer, Stem Cell Society and Principal Scientist, BTI



# SPEAKER

**Dr. Natalie Mount, Cell Therapy Catapult, UK**

**Accelerating Commercialisation of Cell Based Therapies**

## **Abstract**

The Cell Therapy Catapult is a newly established centre for the acceleration of the translation of cell therapies towards commercialisation to support the growth of the cell therapy industry in the United Kingdom. The centre is core funded by the UK Government as a not-for-profit company. Based at Guy's Hospital in London, the Catapult takes selected products into clinical trials, derisking them for further investment. The organization also provides clinical and EU regulatory expertise, access to UK health system (NHS) clinical partners, manufacturing technical expertise and infrastructure as well as access to business expertise, grants and investment finance. The Catapult collaborates nationally and globally.

## **Biography**

Natalie is the Chief Clinical Officer at the Cell Therapy Catapult, the UK's centre for the acceleration of the translation of cell therapies towards commercialisation. Natalie has been responsible for the Clinical Development, Regulatory and Clinical Trials activities at the Catapult since September 2012.

Natalie has a first class degree in Natural Sciences from the University of Cambridge and a PhD from University College, London. Natalie has strong expertise in the clinical development of cell therapies as a major emerging area of medicine. She has 16 years of experience in the Pharmaceutical Industry, including leading cell therapy development programs for a major pharma and previously ran a consultancy advising biotechs on clinical development of cell therapies.